SEC Form 4 · accession 0001209191-16-149265
FIVE PRIME THERAPEUTICS INC · FPRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Peder Jensen
Director
Period of report
Nov 9, 2016
Accepted (ET)
Nov 10, 2016 · 1:53 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001175505
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 9, 2016 | M | 4,065 | $5.54 | A | 4,065 | D | |
| Common Stock | Nov 9, 2016 | M | 4,065 | $7.26 | A | 8,130 | D | |
| Common Stock | Nov 9, 2016 | S | 8,130 | $55.30 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $5.54 | Nov 9, 2016 | M | 4,065 | A | — | Jul 10, 2022 | Common Stock | 4,065 | 0 | D |
| Stock Option (right to buy)F2 | $7.26 | Nov 9, 2016 | M | 4,065 | A | — | Jul 18, 2023 | Common Stock | 4,065 | 0 | D |
Explanation of responses
- F1The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on April 5, 2016.
- F2This option is fully vested and immediately exercisable.